{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:37:40Z","timestamp":1793853460804,"version":"4.6.1"},"reference-count":308,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Wroclaw Medical University, Poland","award":["IDUB.A46B.24.002"],"award-info":[{"award-number":["IDUB.A46B.24.002"]}]},{"name":"Development Strategy of the Wroclaw Medical University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Heart failure (HF) remains a major global health challenge, characterized by high morbidity, mortality, and healthcare costs despite substantial advances in pharmacological, device-based, and structural therapies. Its increasing prevalence reflects population ageing, improved survival after myocardial infarction, and the rising burden of cardiometabolic disease, while growing clinical heterogeneity across the ejection fraction spectrum demands more precise diagnostic and therapeutic strategies.<\/jats:p>\n                  <jats:p>This state-of-the-art review summarizes contemporary HF evidence published in the European Journal of Heart Failure and ESC Heart Failure Journal, integrating recent advances in epidemiology, aetiology, diagnostics, and treatment. Emerging data underscore the role of multi-parametric biomarkers, advanced imaging, and artificial intelligence\u2013based tools in enabling earlier diagnosis, refined risk stratification, and personalized management. Aetiology-specific insights\u2014including hypertensive and ischaemic heart disease, cardiomyopathies, amyloidosis, and pregnancy-related HF\u2014are reshaping clinical pathways and therapeutic decision-making.<\/jats:p>\n                  <jats:p>Major developments in guideline-directed medical therapy are reviewed, including early and intensive initiation strategies, expanding evidence for sodium\u2013glucose cotransporter 2 inhibitors and mineralocorticoid receptor antagonists across the spectrum of ejection fraction, and persistent gaps between trial evidence and real-world implementation. Advances in decongestion, cardio\u2013renal interactions, structural valve interventions, and device-based monitoring further illustrate the evolving complexity of HF care.<\/jats:p>\n                  <jats:p>Despite an expanding therapeutic armamentarium, delayed diagnosis, underuse of evidence-based therapies, and organizational barriers continue to limit clinical impact. Bridging this implementation gap through earlier prevention, precision phenotyping, and integrated multidisciplinary care is essential to improving outcomes for HF patients.<\/jats:p>","DOI":"10.1093\/ejhf\/xuag015","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T12:27:10Z","timestamp":1768307230000},"page":"1-21","source":"Crossref","is-referenced-by-count":3,"title":["Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal"],"prefix":"10.1093","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-7722","authenticated-orcid":false,"given":"Jan","family":"Biegus","sequence":"first","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Wroclaw Medical University, Institute of Heart Diseases , Borowska 213, Wroclaw 50-556 ,","place":["Poland"]},{"name":"Jan Mikulicz Radecki University Hospital in Wroc\u0142aw , Department of Cardiology, Wroclaw 50-556 ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3044-197X","authenticated-orcid":false,"given":"Antoni","family":"Bayes-Genis","sequence":"additional","affiliation":[{"name":"CIBERCV, University Hospital Germans Trias i Pujol , Badalona, Barcelona ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-042X","authenticated-orcid":false,"given":"Stephan","family":"von Haehling","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Pneumology, University G\u00f6ttingen Medical Center (UMG) , G\u00f6ttingen ,","place":["Germany"]},{"name":"DZHK (German Centre for Cardiovascular Research), partner site Lower Saxony , Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Kosmala","sequence":"additional","affiliation":[{"name":"Jan Mikulicz Radecki University Hospital in Wroc\u0142aw , Department of Cardiology, Wroclaw 50-556 ,","place":["Poland"]},{"name":"Department of Cardiovascular Imaging, Faculty of Medicine, Wroclaw Medical University, Institute of Heart Diseases , Wroclaw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Markwirth","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Saarland University Medical Center and Saarland University , Kirrberger Str. 100, Homburg 66421 ,","place":["Germany"]},{"name":"Medical Faculty, HOMICAREM (HOMburg Institute of CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-1542","authenticated-orcid":false,"given":"Zolt\u00e1n","family":"Papp","sequence":"additional","affiliation":[{"name":"Division of Clinical Physiology, Department of Cardiology, Faculty of Medicine, University of Debrecen , Debrecen ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Wroclaw Medical University, Institute of Heart Diseases , Borowska 213, Wroclaw 50-556 ,","place":["Poland"]},{"name":"Jan Mikulicz Radecki University Hospital in Wroc\u0142aw , Department of Cardiology, Wroclaw 50-556 ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[{"name":"Department of Clinical Science and Education, S\u00f6dersjukhuset Karolinska Institutet , Sjukhusbacken 10, Stockholm 118 83 ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Tkaczyszyn","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Clinical Department of Intensive Cardiac Care, Faculty of Medicine, Wroclaw Medical University, Institute of Heart Diseases , Borowska 213, Wroclaw 50-556 ,","place":["Poland"]},{"name":"Jan Mikulicz Radecki University Hospital in Wroc\u0142aw , Department of Cardiology, Wroclaw 50-556 ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mert","family":"Tokcan","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Saarland University Medical Center and Saarland University , Kirrberger Str. 100, Homburg 66421 ,","place":["Germany"]},{"name":"Medical Faculty, HOMICAREM (HOMburg Institute of CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2514","authenticated-orcid":false,"given":"Michael","family":"B\u00f6hm","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III\u2014Kardiologie, Angiologie und Internistische Intensivmedizin, Saarland University Medical Center and Saarland University , Kirrberger Str. 100, Homburg 66421 ,","place":["Germany"]},{"name":"Medical Faculty, HOMICAREM (HOMburg Institute of CArdioREnalMetabolic Medicine), Saarland University , Homburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,17]]},"reference":[{"key":"2026050209115475600_xuag015-B1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/ejhf.3506","article-title":"Trends in heart failure mortality in Sweden between 1997 and 2022","volume":"27","author":"Lindberg","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1002\/ejhf.3499","article-title":"Long-term clinical outcomes and healthcare resource utilization in male and female patients following hospitalization for heart failure","volume":"27","author":"Averbuch","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B3","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/ejhf.2874","article-title":"Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B4","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1002\/ejhf.2831","article-title":"Health status across major subgroups of patients with heart failure and preserved ejection fraction","volume":"25","author":"Siddiqi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B5","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/ejhf.3517","article-title":"Psychological distress in heart failure patients: implications for healthcare utilization and expenditure","volume":"27","author":"Thyagaturu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B6","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/ehf2.15265","article-title":"Survival after myocardial infarction according to left ventricular function and heart failure symptoms","volume":"12","author":"Jortveit","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B7","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/ehf2.14474","article-title":"A nationwide study of temporal trends of cause-specific hospital readmissions in patients with heart failure","volume":"10","author":"Kontogeorgos","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B8","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/ejhf.3352","article-title":"Geographical variation in patient characteristics and outcomes in heart failure with mildly reduced and preserved ejection fraction","volume":"26","author":"Yang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B9","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ejhf.70001","article-title":"Heart failure-attributed mortality in Europe, 2012\u20132021","volume":"27","author":"Zuin","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B10","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1002\/ejhf.3496","article-title":"The 25in25 initiative: a novel transformative project to reduce mortality due to heart failure by 25% in the next 25 years","volume":"26","author":"Savage","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1002\/ehf2.14687","article-title":"Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement","volume":"11","author":"Chioncel","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B13","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ejhf.2115","article-title":"Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association","volume":"23","author":"Bozkurt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ejhf.3155","article-title":"Association between secondhand smoke exposure and incident heart failure: the Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"26","author":"Lin","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1002\/ejhf.3176","article-title":"Association of diabetes-specific heart failure risk score with presence of subclinical cardiomyopathy among individuals with diabetes: a prospective study","volume":"26","author":"Chunawala","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B16","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1002\/ejhf.3443","article-title":"Development and validation of a machine learning-based approach to identify high-risk diabetic cardiomyopathy phenotype","volume":"26","author":"Segar","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B17","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/ejhf.2970","article-title":"Prediction models for heart failure in the community: a systematic review and meta-analysis","volume":"25","author":"Nadarajah","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B18","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1002\/ejhf.2965","article-title":"Declining risk of heart failure hospitalization following first acute myocardial infarction in Scotland between 1991\u20132016","volume":"25","author":"Docherty","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B19","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/ehf2.14497","article-title":"Epidemiology and treatment of heart failure with chronic obstructive pulmonary disease in Canadian primary care","volume":"10","author":"Hawkins","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B20","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1002\/ejhf.2962","article-title":"Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction","volume":"25","author":"Yang","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B21","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1002\/ejhf.3071","article-title":"Interaction of heart failure and stroke: a clinical consensus statement of the ESC Council on Stroke, the Heart Failure Association (HFA) and the ESC Working Group on Thrombosis","volume":"25","author":"Doehner","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B22","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1002\/ejhf.3210","article-title":"Identification and outcomes of KDIGO-defined chronic kidney disease in 1.4 million U.S. Veterans with heart failure","volume":"26","author":"Patel","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B23","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/ehf2.15127","article-title":"Phenotyping patients with chronic obstructive pulmonary disease and heart failure","volume":"12","author":"Becher","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B24","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1002\/ejhf.3112","article-title":"The role of multimorbidity in patients with heart failure across the left ventricular ejection fraction spectrum: data from the Swedish Heart Failure Registry","volume":"26","author":"Tomasoni","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B25","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/ejhf.3642","article-title":"How to handle polypharmacy in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC","volume":"27","author":"Stolfo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B26","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70090","article-title":"Adherence to guideline-directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy","volume":"27","author":"Savarese","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B27","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1002\/ejhf.2895","article-title":"Prevalence, characteristics and cardiovascular and non-cardiovascular outcomes in patients with heart failure with supra-normal ejection fraction: insight from the JROADHF study","volume":"25","author":"Horiuchi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ejhf.2811","article-title":"Time to reconsider the perception and management of hypertensive heart disease","volume":"25","author":"D\u00edez","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B29","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ejhf.3108","article-title":"Blood pressure levels and adverse cardiovascular outcomes in heart failure: a systematic review and meta-analysis","volume":"26","author":"Seidu","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B30","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jchf.2022.04.006","article-title":"Apparent treatment-resistant hypertension across the spectrum of heart failure phenotypes in the Swedish HF Registry","volume":"10","author":"Jackson","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B31","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1002\/ehf2.15232","article-title":"Association of baseline eGFR and incident heart failure on patients receiving intensive blood pressure treatment","volume":"12","author":"Haonan","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B32","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/j.jchf.2023.01.006","article-title":"Degree of joint risk factor control and incident heart failure in hypertensive patients","volume":"11","author":"Kou","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B33","doi-asserted-by":"publisher","first-page":"e011724","DOI":"10.1161\/circheartfailure.124.011724","article-title":"Unraveling comorbidities contribution to cardiac diastolic dysfunction and heart failure","volume":"18","author":"Villalba-Orero","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026050209115475600_xuag015-B34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/ejhf.2827","article-title":"Deep phenotype characterization of hypertensive response to exercise: implications on functional capacity and prognosis across the heart failure spectrum","volume":"25","author":"Pugliese","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41371-025-01079-5","article-title":"Exaggerated blood pressure response to submaximal exercise and cardiac target organ damage: importance of fitness","volume":"39","author":"Zachwyc","year":"2025","journal-title":"J Hum Hypertens"},{"key":"2026050209115475600_xuag015-B36","doi-asserted-by":"publisher","first-page":"e012459","DOI":"10.1161\/circheartfailure.124.012459","article-title":"Hemodynamics of exercise-induced hypertension and relationship to outcomes in adults with coarctation of the aorta","volume":"18","author":"Egbe","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026050209115475600_xuag015-B37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/ejhf.3520","article-title":"Hypertensive pregnancy disorder, an under-recognized women specific risk factor for heart failure?","volume":"27","author":"Ghossein-Doha","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B38","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.jchf.2023.03.021","article-title":"Pregnancy-induced hypertensive disorder and risks of future ischemic and nonischemic heart failure","volume":"11","author":"Mantel","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B39","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/ehf2.14473","article-title":"Efficacy and safety of baroreflex activation therapy for heart failure with reduced ejection fraction: systematic review","volume":"10","author":"Molina-Linde","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ehf2.15104","article-title":"Baroreflex activation therapy in advanced heart failure: a long-term follow-up","volume":"12","author":"Wang","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B41","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1002\/ehf2.14940","article-title":"Effects of baroreflex activation therapy on cardiac function and morphology","volume":"11","author":"Sch\u00e4fer","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B42","doi-asserted-by":"publisher","first-page":"e010543","DOI":"10.1161\/circheartfailure.123.010543","article-title":"Modulation of pulsatile left ventricular afterload by renal denervation in heart failure with preserved ejection fraction","volume":"16","author":"Rommel","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026050209115475600_xuag015-B43","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1093\/eurheartj\/ehae672","article-title":"Coronary artery bypass grafting vs. percutaneous coronary intervention in severe ischaemic cardiomyopathy: long-term survival","volume":"46","author":"Bloom","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B44","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jchf.2024.03.010","article-title":"Effect of PCI on health status in ischemic left ventricular dysfunction: insights from REVIVED-BCIS2","volume":"12","author":"Ryan","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B45","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"key":"2026050209115475600_xuag015-B46","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1093\/eurheartj\/ehac670","article-title":"Surgical or percutaneous coronary revascularization for heart failure: an in silico model using routinely collected health data to emulate a clinical trial","volume":"44","author":"Pathak","year":"2023","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B47","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1002\/ejhf.2911","article-title":"Coronary revascularization for heart failure with coronary artery disease: a systematic review and meta-analysis of randomized trials","volume":"25","author":"Iaconelli","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B48","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.3463","article-title":"Revascularization and outcomes in ischaemic left ventricular dysfunction after heart failure admission: the RevascHeart study","volume":"27","author":"Moliner-Ab\u00f3s","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B49","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1002\/ehf2.14445","article-title":"Mortality rate after coronary revascularization in heart failure patients with coronary artery disease","volume":"10","author":"Nader","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B50","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1093\/eurheartj\/ehae341","article-title":"Cardiac shockwave therapy in addition to coronary bypass surgery improves myocardial function in ischaemic heart failure: the CAST-HF trial","volume":"45","author":"Holfeld","year":"2024","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B51","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1093\/eurheartj\/ehae885","article-title":"Incident heart failure and recurrent coronary events following acute myocardial infarction","volume":"46","author":"Butler","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B52","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1016\/j.jacc.2024.03.405","article-title":"Left ventricular function, congestion, and effect of empagliflozin on heart failure risk after myocardial infarction","volume":"83","author":"Udell","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"2026050209115475600_xuag015-B53","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1161\/circulationaha.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"key":"2026050209115475600_xuag015-B54","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1002\/ehf2.14626","article-title":"Impact of coronary microvascular dysfunction in heart failure with preserved ejection fraction: a meta-analysis","volume":"11","author":"D'Amario","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B55","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1002\/ehf2.14281","article-title":"Danish phase II trial using adipose tissue derived mesenchymal stromal cells for patients with ischaemic heart failure","volume":"10","author":"Qayyum","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B56","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/ejhf.2772","article-title":"Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction\u2014the SCIENCE trial","volume":"25","author":"Qayyum","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B57","doi-asserted-by":"publisher","first-page":"102528","DOI":"10.1016\/j.jchf.2025.102528","article-title":"Cardiac magnetic resonance imaging vs coronary angiography as primary strategy in newly diagnosed heart failure","volume":"13","author":"G\u00fcder","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B58","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1161\/circulationaha.123.067032","article-title":"Nonischemic or dual cardiomyopathy in patients with coronary artery disease","volume":"149","author":"Bawaskar","year":"2024","journal-title":"Circulation"},{"key":"2026050209115475600_xuag015-B59","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.jchf.2023.07.013","article-title":"Impact of coronary artery disease in women with newly diagnosed heart failure and reduced ejection fraction","volume":"11","author":"Nielsen","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B60","doi-asserted-by":"publisher","first-page":"e010426","DOI":"10.1161\/circheartfailure.122.010426","article-title":"Long-term outcomes of early coronary artery disease testing after new-onset heart failure","volume":"16","author":"Zheng","year":"2023","journal-title":"Circ Heart Fail"},{"key":"2026050209115475600_xuag015-B61","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.jchf.2024.08.010","article-title":"Cardiac resynchronization therapy in ischemic vVs nonischemic cardiomyopathy: patient-level meta-analysis of 7 randomized clinical trials","volume":"12","author":"Sudesh","year":"2024","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B62","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1002\/ejhf.3731","article-title":"Implantable cardioverter-defibrillators in ischaemic vs non-ischaemic heart failure: insights from the VICTORIA trial","volume":"27","author":"Gouda","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B63","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ehf2.14465","article-title":"Phenotyping patients with ischaemic heart disease at risk of developing heart failure: an analysis of the HOMAGE trial","volume":"11","author":"Santos-Ferreira","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B64","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ehf2.15133","article-title":"Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy","volume":"12","author":"Borger","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B65","doi-asserted-by":"publisher","first-page":"963","DOI":"10.17219\/dmp\/210102","article-title":"Smoldering inflammation: the silent flame driving heart failure","volume":"62","author":"Wilk","year":"2025","journal-title":"Dent Med Probl"},{"key":"2026050209115475600_xuag015-B66","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ejhf.3033","article-title":"Assessing the association between genetic and phenotypic features of dilated cardiomyopathy and outcome in patients with coronary artery disease","volume":"26","author":"Jones","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B67","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1002\/ejhf.3497","article-title":"New cardiovascular biomarkers in patients with advanced cancer\u2014a prospective study comparing MR-proADM, MR-proANP, copeptin, high-sensitivity troponin T and NT-proBNP","volume":"27","author":"Anker","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B68","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1002\/ejhf.3576","article-title":"Circulating growth differentiation factor-15 levels are associated with early echocardiographic signs of diastolic function impairment in the STANISLAS cohort: a 20-year follow-up study","volume":"27","author":"Monzo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B69","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1002\/ejhf.3613","article-title":"Growth differentiation factor-15: a promising biomarker for early detection of pre-heart failure","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B70","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/ehf2.15068","article-title":"Growth differentiation factor-15 and N-terminal pro-BNP in acute heart failure with preserved ejection fraction","volume":"12","author":"Otaki","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B71","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/ehf2.15051","article-title":"IL-2R\u03b1 is a potential biomarker for heart failure diagnosis of patients with end-stage renal disease and haemodialysis","volume":"12","author":"Lv","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B72","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1002\/ehf2.15037","article-title":"Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome","volume":"11","author":"Yndigegn","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B73","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/ejhf.3632","article-title":"Urinary sodium analysis: the key to effective diuretic titration? European Journal of Heart Failure expert consensus document","volume":"27","author":"Meekers","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B74","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1002\/ejhf.70079","article-title":"Urinary markers in heart failure\u2014types, timing and thresholds. European Journal of Heart Failure expert consensus document","volume":"27","author":"Kobayashi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B75","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1002\/ejhf.3597","article-title":"Salt repletion and diuretic response: the role of serum chloride. A post-hoc analysis of the SALT-HF trial on furosemide and hypertonic saline solution administration in ambulatory patients with worsening heart failure","volume":"27","author":"N\u00fa\u00f1ez","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B76","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/ejhf.3693","article-title":"Home-based urinary sodium monitoring via point-of-care testing for personalized diuretic titration in heart failure management: the EASY-STOP study","volume":"27","author":"Meekers","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B77","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1002\/ejhf.3683","article-title":"Albuminuria as a diagnostic criterion and a therapeutic target in heart failure and other cardiovascular disease","volume":"27","author":"Bozkurt","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B78","doi-asserted-by":"publisher","first-page":"3470","DOI":"10.1002\/ehf2.14811","article-title":"Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction","volume":"11","author":"Min","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B79","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/ejhf.3739","article-title":"Serially measured urinary albumin excretion is strongly associated with incident heart failure with preserved ejection fraction","volume":"27","author":"Kok","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B80","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ehf2.15128","article-title":"eGFR slope as predictor of mortality in heart failure patients","volume":"12","author":"Verstreken","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B81","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1002\/ehf2.15383","article-title":"Age-adjusted natriuretic peptide thresholds for a diagnosis of heart failure in the community: diagnostic accuracy study","volume":"12","author":"Taylor","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B82","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1002\/ejhf.3694","article-title":"Effects of finerenone on natriuretic peptide levels in heart failure with mildly reduced or preserved ejection fraction: the FINEARTS-HF trial","volume":"27","author":"Cunningham","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B83","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3651","article-title":"A simplified approach for diagnosing heart failure with preserved ejection fraction by assessing the left atrium and natriuretic peptides","volume":"27","author":"Weerts","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B84","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/ejhf.2979","article-title":"State-of-the-art document on optimal contemporary management of cardiomyopathies","volume":"25","author":"Seferovi\u0107","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B85","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1002\/ejhf.3076","article-title":"Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies","volume":"25","author":"Polovina","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B86","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/ejhf.3556","article-title":"Guideline-directed medical therapy for heart failure in arrhythmia-induced cardiomyopathy with improved left ventricular ejection fraction","volume":"27","author":"Dom\u00ednguez-Rodr\u00edguez","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B87","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/ejhf.3594","article-title":"Withdrawal of medical therapy for heart failure after rhythm control in arrhythmia-induced cardiomyopathy-a call for caution","volume":"27","author":"Girerd","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B88","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/ejhf.2768","article-title":"Mavacamten in obstructive hypertrophic cardiomyopathy\u2014are beta-blockers blocking part of its shine?","volume":"25","author":"Dominguez","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B89","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1002\/ejhf.2737","article-title":"Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy","volume":"25","author":"Wheeler","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B90","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ejhf.3120","article-title":"Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population","volume":"26","author":"Bertero","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B91","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ejhf.3291","article-title":"Sacubitril\/valsartan for the treatment of non-obstructive hypertrophic cardiomyopathy: an open label randomized controlled trial (SILICOFCM)","volume":"26","author":"Velicki","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B92","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/ejhf.3055","article-title":"Outcomes at one year in women with peripartum cardiomyopathy: findings from the ESC EORP PPCM registry","volume":"26","author":"Jackson","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B93","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1002\/ejhf.2871","article-title":"Thromboembolic events in peripartum cardiomyopathy: results from the ESC EORP PPCM registry","volume":"25","author":"Tromp","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B94","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1002\/ejhf.2937","article-title":"Thromboembolic events in peripartum cardiomyopathy: current dilemmas and future perspectives","volume":"25","author":"Monda","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B95","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/ejhf.1493","article-title":"Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy","volume":"21","author":"Bauersachs","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B96","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1002\/ejhf.2133","article-title":"Risk stratification and management of women with cardiomyopathy\/heart failure planning pregnancy or presenting during\/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy","volume":"23","author":"Sliwa","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B97","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1002\/ejhf.3246","article-title":"Multidisciplinary care of peripartum heart failure: a scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Rakisheva","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B98","doi-asserted-by":"publisher","first-page":"3649","DOI":"10.1002\/ehf2.15035","article-title":"Transthyretin cardiac amyloid: broad heart failure phenotypic spectrum and implications for diagnosis","volume":"11","author":"Alonso","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B99","doi-asserted-by":"publisher","first-page":"4314","DOI":"10.1002\/ehf2.14971","article-title":"Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy","volume":"11","author":"Garcia-Pavia","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B100","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1002\/ehf2.15126","article-title":"Real-world characteristics and treatment of cardiac transthyretin amyloidosis: a multicentre, observational study","volume":"12","author":"Nies","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B101","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1002\/ejhf.3339","article-title":"Evaluation of the 2021 ESC recommendations for family screening in hereditary transthyretin cardiac amyloidosis","volume":"26","author":"Muller","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B102","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/ejhf.3088","article-title":"Deep phenotyping of p.(V142I)-associated variant transthyretin amyloid cardiomyopathy: distinct from wild-type transthyretin amyloidosis?","volume":"26","author":"Razvi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B103","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1002\/ehf2.14736","article-title":"Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan","volume":"11","author":"Kato","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B104","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1093\/eurheartj\/ehae923","article-title":"Tafamidis in octogenarians with wild-type transthyretin cardiac amyloidosis: an international cohort study","volume":"46","author":"Debonnaire","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B105","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3696","article-title":"Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage","volume":"27","author":"Damy","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B106","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1002\/ejhf.3330","article-title":"Long-term tafamidis efficacy in patients with transthyretin amyloid cardiomyopathy by baseline left ventricular ejection fraction","volume":"26","author":"Drachman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B107","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"2026050209115475600_xuag015-B108","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"26","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B109","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"2026050209115475600_xuag015-B110","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"key":"2026050209115475600_xuag015-B111","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1016\/j.jacc.2025.04.008","article-title":"Vutrisiran improves survival and reduces cardiovascular events in ATTR amyloid cardiomyopathy: HELIOS-B","volume":"85","author":"Witteles","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026050209115475600_xuag015-B112","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1038\/s41591-025-03851-z","article-title":"Effects of vutrisiran on cardiac structure and function in patients with transthyretin amyloidosis with cardiomyopathy: secondary outcomes of the HELIOS-B trial","volume":"31","author":"Jering","year":"2025","journal-title":"Nat Med"},{"key":"2026050209115475600_xuag015-B113","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70084","article-title":"Efficacy and safety of vutrisiran in transthyretin amyloid cardiomyopathy across the age spectrum: the HELIOS-B trial","volume":"27","author":"Sheikh","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B114","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.jacc.2025.03.477","article-title":"Impact of heart failure severity on vutrisiran efficacy in transthyretin amyloidosis with cardiomyopathy","volume":"85","author":"Maurer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"2026050209115475600_xuag015-B115","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1002\/ejhf.3198","article-title":"Sodium-glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: analyses of short-term efficacy and safety","volume":"26","author":"Lang","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B116","doi-asserted-by":"publisher","first-page":"3901","DOI":"10.1002\/ehf2.14975","article-title":"Effect of beta-blockade on mortality in patients with cardiac amyloidosis: a systematic review and meta-analysis","volume":"11","author":"Kwok","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B117","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1093\/eurheartj\/ehaf710","article-title":"Non-amyloid specific treatment for transthyretin cardiac amyloidosis: a clinical consensus statement of the ESC Heart Failure Association","volume":"47","author":"Garcia-Pavia","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B118","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1093\/eurheartj\/ehaf450","article-title":"Artificial intelligence-enabled electrocardiography and echocardiography to track preclinical progression of transthyretin amyloid cardiomyopathy","volume":"46","author":"Oikonomou","year":"2025","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B119","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3455","article-title":"The Mayo ATTR-CM score vs other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis","volume":"27","author":"Bonfioli","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B120","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1002\/ejhf.3354","article-title":"Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis","volume":"26","author":"Nitsche","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B121","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3481","article-title":"Microvascular obstruction in cardiac amyloidosis","volume":"27","author":"Netti","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B122","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.3137","article-title":"Myocardial perfusion in cardiac amyloidosis","volume":"26","author":"Chacko","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B123","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ehf2.15105","article-title":"Implementation of guideline-recommended medical therapy for patients with heart failure in Europe","volume":"12","author":"Volterrani","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B124","doi-asserted-by":"publisher","first-page":"3826","DOI":"10.1002\/ehf2.15389","article-title":"Early in-hospital treatment of acute heart failure. Part 2 of the international expert opinion series on AHF management","volume":"12","author":"Naidu","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B125","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1002\/ejhf.2985","article-title":"Decongestion strategies in patients presenting with acutely decompensated heart failure: a worldwide survey among physicians","volume":"25","author":"Vazir","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B126","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1002\/ehf2.14920","article-title":"Loop diuretics in heart failure: the objective markers to guide the therapy are needed","volume":"11","author":"Biegus","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B127","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.13372","article-title":"Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge","volume":"8","author":"Biegus","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B128","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.1002\/ehf2.15439","article-title":"Determinants of diuresis\/natriuresis following ambulatory intravenous loop diuretics for worsening heart failure","volume":"12","author":"Massin","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B129","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1002\/ehf2.14883","article-title":"Spot urine sodium-to-creatinine ratio surpasses sodium in identifying poor diuretic response in acute heart failure","volume":"11","author":"Iwanek","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B130","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1002\/ehf2.15275","article-title":"Early diuretic response and outcome prediction in ambulatory worsening heart failure: natriuresis vs diuresis","volume":"12","author":"Cobo Marcos","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B131","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1038\/s41591-023-02532-z","article-title":"Natriuresis-guided diuretic therapy in acute heart failure: a pragmatic randomized trial","volume":"29","author":"Ter Maaten","year":"2023","journal-title":"Nat Med"},{"key":"2026050209115475600_xuag015-B132","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/ejhf.3228","article-title":"Renal function and natriuresis-guided diuretic therapy\u2014a pre-specified analysis from the PUSH-AHF trial","volume":"26","author":"Damman","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B133","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/ejhf.2053","article-title":"Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients","volume":"23","author":"Biegus","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B134","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1002\/ehf2.14755","article-title":"Fractional excretion of urea nitrogen can identify true worsening renal function in patients with heart failure","volume":"11","author":"Watanabe","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B135","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.1002\/ehf2.15342","article-title":"Proteins associated with rehospitalization, mortality and diuretic resistance in acutely decompensated heart failure","volume":"12","author":"Hubbell","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B136","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ehf2.15069","article-title":"Prevalence and characteristics of upfront diuretic resistance in acute heart failure: the P-Value-AHF study","volume":"12","author":"Baumberger","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B137","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1002\/ejhf.2852","article-title":"The blunted loop diuretic response in acute heart failure is driven by reduced tubular responsiveness rather than insufficient tubular delivery. The role of furosemide urine excretion on diuretic and natriuretic response in acute heart failure","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B138","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70080","article-title":"Outpatient loop diuretic use and the effect of natriuresis-guided diuretic therapy: a prespecified sub-analysis of the PUSH-AHF study","volume":"27","author":"Zonneveld","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B139","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/ejhf.3429","article-title":"Nurse-led diuretic titration via a point-of-care urinary sodium sensor in patients with acute decompensated heart failure (EASY-HF): a single-centre, randomized, open-label study","volume":"26","author":"Meekers","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B140","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1002\/ejhf.3390","article-title":"Efficacy and safety of hypertonic saline therapy in ambulatory patients with heart failure: the SALT-HF trial","volume":"26","author":"Cobo Marcos","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B141","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/ejhf.3500","article-title":"Exploring the role of hypertonic saline in ambulatory heart failure management: one size does not fit all?","volume":"27","author":"Girerd","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B142","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/ejhf.3708","article-title":"Sodium chloride vs glucose solute as a volume replacement therapy for more effective decongestion in acute heart failure (SOLVRED-AHF): a prospective, randomized, mechanistic study","volume":"27","author":"Biegus","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B143","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/ehf2.15054","article-title":"Urine chloride trajectory and relationship with diuretic response in acute heart failure","volume":"12","author":"Guzik","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B144","doi-asserted-by":"publisher","first-page":"14100","DOI":"10.1038\/s41598-024-64747-5","article-title":"The role of urine chloride in acute heart failure","volume":"14","author":"Nawrocka-Millward","year":"2024","journal-title":"Sci Rep"},{"key":"2026050209115475600_xuag015-B145","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70081","article-title":"The chloride paradigm shift in heart failure: from neglected ion to keystone of precision diuretic therapy","volume":"27","author":"Mazon-Ruiz","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B146","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/ejhf.3244","article-title":"Dietary sodium and fluid intake in heart failure. A clinical consensus statement of the Heart Failure Association of the ESC","volume":"26","author":"Mullens","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B147","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00392-023-02256-7","article-title":"Role of dietary sodium restriction in chronic heart failure: systematic review and meta-analysis","volume":"113","author":"Urban","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026050209115475600_xuag015-B148","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.3131","article-title":"Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: mechanistic insights into sodium handling","volume":"26","author":"Dauw","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B149","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1038\/s41591-025-03628-4","article-title":"Liberal fluid intake vs fluid restriction in chronic heart failure: a randomized clinical trial","volume":"31","author":"Herrmann","year":"2025","journal-title":"Nat Med"},{"key":"2026050209115475600_xuag015-B150","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1002\/ejhf.3423","article-title":"Decongestion in acute heart failure: is it time to change diuretic-centred paradigm?","volume":"26","author":"Biegus","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B151","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/ejhf.3265","article-title":"Reduced congestion and improved response to a fluid\/sodium challenge in chronic heart failure patients after initiation of sacubitril\/valsartan: the NATRIUM-HF study","volume":"26","author":"Mebazaa","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B152","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.jchf.2025.03.010","article-title":"Diuretic de-escalation in response to HF therapy: are we closer to reduced reliance on diuretics?","volume":"13","author":"Biegus","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B153","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/ejhf.2882","article-title":"Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: insights from the STRONG-HF trial","volume":"25","author":"Cerlinskaite-Bajore","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B154","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/ejhf.2920","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: a sub-analysis of the STRONG-HF randomized clinical trial","volume":"25","author":"Arrigo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B155","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1002\/ejhf.3039","article-title":"Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: insights from the STRONG-HF trial","volume":"25","author":"Chioncel","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B156","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1002\/ejhf.3074","article-title":"Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure","volume":"25","author":"Ter Maaten","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B157","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1002\/ehf2.15156","article-title":"Socio-economic status and the effect of guideline-directed medical therapy in the STRONG-HF study","volume":"12","author":"Damasceno","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B158","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1002\/ejhf.3267","article-title":"Contemporary guideline-directed medical therapy in de novo, chronic, and worsening heart failure patients: first data from the TITRATE-HF study","volume":"26","author":"Malgie","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B159","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1002\/ejhf.3214","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the Heart Failure Association of the ESC and the ESC Council for Cardiology Practice","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B160","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ejhf.3072","article-title":"Short-term effects of sacubitril\/valsartan therapy on myocardial oxygen consumption and energetic efficiency of cardiac work in heart failure with reduced ejection fraction: a randomized controlled study","volume":"26","author":"Nesterov","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B161","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ejhf.3079","article-title":"Sacubitril\/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: insight from the PARADISE MI trial","volume":"26","author":"Schou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B162","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ejhf.3383","article-title":"Beta-blocker use and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction","volume":"27","author":"Matsumoto","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B163","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/ejhf.2975","article-title":"Mineralocorticoid receptor antagonist initiation during admission is associated with improved outcomes irrespective of ejection fraction in patients with acute heart failure","volume":"25","author":"Beldhuis","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B164","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.1954","article-title":"Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B165","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1002\/ejhf.2026","article-title":"Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure","volume":"22","author":"Seferovi\u0107","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B166","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"26","author":"McDonagh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B167","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1002\/ejhf.2735","article-title":"Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B168","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/ejhf.2766","article-title":"Little at a time: trying to understand the battery of benefits of sodium-glucose contransporter 2 inhibitors in heart failure","volume":"25","author":"von Haehling","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B169","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/ejhf.2782","article-title":"Letter regarding the article \u2018Little at a time: trying to understand the battery of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure\u2019","volume":"25","author":"Fuchs Andersen","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B170","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1002\/ejhf.2884","article-title":"Impact of dapagliflozin on cardiac remodelling in patients with chronic heart failure: the DAPA-MODA study","volume":"25","author":"Pascual-Figal","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B171","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2131","article-title":"Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry","volume":"23","author":"Becher","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B172","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/ejhf.2777","article-title":"Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure","volume":"25","author":"Miller","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B173","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B174","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ejhf.3197","article-title":"Cost-effectiveness of dapagliflozin for patients with heart failure across the spectrum of ejection fraction: a pooled analysis of DAPA-HF and DELIVER data","volume":"26","author":"Davis","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B175","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/ejhf.3404","article-title":"Status and timing of angiotensin receptor-neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry","volume":"26","author":"Stolfo","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B176","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/ejhf.3445","article-title":"Heart failure in Europe: guideline-directed medical therapy use and decision making in chronic and acute, pre-existing and de novo, heart failure with reduced, mildly reduced, and preserved ejection fraction\u2014the ESC EORP Heart Failure III Registry","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B177","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ejhf.2971","article-title":"Real-world use of sodium-glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: data from the Swedish Heart Failure Registry","volume":"25","author":"Stolfo","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B178","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/ejhf.2798","article-title":"Personalized care of patients with heart failure: are we ready for a REWOLUTION? Insights from two international surveys on healthcare professionals\u2019 needs and patients\u2019 perceptions","volume":"25","author":"Jankowska","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B179","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/ejhf.2892","article-title":"Patient profiles in heart failure with reduced ejection fraction: prevalence, characteristics, treatments and outcomes in a real-world heart failure population","volume":"25","author":"Musella","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B180","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/ejhf.3174","article-title":"Blood pressure and intensive treatment up-titration after acute heart failure hospitalization: insights from the STRONG-HF trial","volume":"26","author":"Pagnesi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B181","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1002\/ejhf.3049","article-title":"Safety of continuing mineralocorticoid receptor antagonist treatment in patients with heart failure with reduced ejection fraction and severe kidney disease: data from Swedish Heart Failure Registry","volume":"25","author":"Guidetti","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B182","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC","volume":"26","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B183","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1002\/ejhf.3444","article-title":"Translating the 2021 ESC heart failure guideline recommendations in daily practice: results from a heart failure survey. A scientific statement of the ESC Council for Cardiology Practice and the Heart Failure Association of the ESC","volume":"27","author":"Christodorescu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B184","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1002\/ejhf.3530","article-title":"Knowledge and application of ESC\/HFA guidelines in the management of advanced heart failure","volume":"27","author":"Baudry","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B185","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/ejhf.3523","article-title":"Discontinuation and reinitiation of mineralocorticoid receptor antagonists in patients with heart failure and reduced ejection fraction","volume":"27","author":"Landucci","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B186","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1002\/ejhf.2879","article-title":"Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project","volume":"25","author":"Lindberg","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B187","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/ejhf.3150","article-title":"Integration of implantable device therapy in patients with heart failure. A clinical consensus statement from the Heart Failure Association (HFA) and European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC)","volume":"26","author":"Mullens","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B188","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/ejhf.2928","article-title":"Association between a hospitalization for heart failure and the initiation\/discontinuation of guideline-recommended treatments: an analysis from the Swedish Heart Failure Registry","volume":"25","author":"Schrage","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B189","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/ejhf.2944","article-title":"Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction","volume":"25","author":"Yang","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B190","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/ejhf.3519","article-title":"Examining the clinical role and educational preparation of heart failure nurses across Europe. A survey of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP) of the ESC","volume":"27","author":"Hill","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B191","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1002\/ejhf.3260","article-title":"OPTImal PHARMacological therapy for patients with heart failure: rationale and design of the OPTIPHARM-HF registry","volume":"26","author":"Inciardi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B192","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1002\/ejhf.3087","article-title":"Rationale and design of the ESC Heart Failure III Registry\u2014implementation and discovery","volume":"25","author":"Lund","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B193","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/ejhf.3631","article-title":"Kidney status and events preceding death in heart failure: a real-world nationwide study","volume":"27","author":"Zahir Anjum","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B194","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1002\/ejhf.3643","article-title":"The role of kidney disease progression in heart failure prognosis: bridging the evidence gap for optimal management","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B195","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1002\/ejhf.3298","article-title":"When chronic kidney disease (CKD) intersects with heart failure: insights and implications of the identification of KDIGO-defined CKD in 1.4 million U.S. Veterans with heart failure","volume":"26","author":"Pitt","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B196","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/ehf2.14601","article-title":"Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease","volume":"11","author":"Sharma","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B197","doi-asserted-by":"publisher","first-page":"3940","DOI":"10.1002\/ehf2.15393","article-title":"Empagliflozin after myocardial infarction with or without diabetes and chronic kidney disease: insights from EMPACT-MI","volume":"12","author":"Fioretti","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B198","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1002\/ejhf.3292","article-title":"Effects of canagliflozin on total heart failure events across the kidney function spectrum: participant-level pooled analysis from the CANVAS Program and CREDENCE trial","volume":"26","author":"Vaduganathan","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B199","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor\u2013neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: a systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B200","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/ejhf.70052","article-title":"Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: findings from FINEARTS-HF","volume":"27","author":"Ferreira","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B201","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ejhf.3569","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by diuretic use: a FIDELITY analysis","volume":"27","author":"Mentz","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B202","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/ejhf.3701","article-title":"Kidney injury in patients with heart failure-related cardiogenic shock: results from an international, multicentre cohort study","volume":"27","author":"Sundermeyer","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B203","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1002\/ejhf.2893","article-title":"Ironing out the wrinkles: unanswered questions in intravenous iron repletion in heart failure","volume":"25","author":"Harrington","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B204","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00392-024-02396-4","article-title":"Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment","volume":"113","author":"von Haehling","year":"2024","journal-title":"Clin Res Cardiol"},{"key":"2026050209115475600_xuag015-B205","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"2026050209115475600_xuag015-B206","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/ejhf.2933","article-title":"Combating therapeutic inertia: optimizing iron deficiency treatment in heart failure","volume":"25","author":"Girerd","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B207","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1002\/ejhf.3051","article-title":"Striving for the \u2018perfect\u2019 definition of iron deficiency in heart failure","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B208","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1002\/ejhf.2949","article-title":"Prognostic value of three iron deficiency definitions in patients with advanced heart failure","volume":"25","author":"Papadopoulou","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B209","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1002\/ejhf.3237","article-title":"Critical re-evaluation of the identification of iron deficiency states and effective iron repletion strategies in patients with chronic heart failure","volume":"26","author":"Packer","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B210","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/ejhf.2816","article-title":"Dosing of iron supplementation for iron-deficient patients with heart failure: should we prefer more intensive or less intensive repletion targets?","volume":"25","author":"Packer","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B211","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1080\/14656566.2024.2418414","article-title":"Pharmacological management of heart failure: a patient-centred approach","volume":"25","author":"Fibbi","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"2026050209115475600_xuag015-B212","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1002\/ehf2.14265","article-title":"Applicability of new proposed criteria for iron deficiency in Japanese patients with heart failure","volume":"10","author":"Tada","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B213","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1002\/ehf2.14438","article-title":"Influence of serum transferrin concentration on diagnostic criteria for iron deficiency in chronic heart failure","volume":"10","author":"Graham","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B214","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1002\/ehf2.14610","article-title":"Relationship between serum iron level and physical function in heart failure patients is lost by presence of diabetes","volume":"11","author":"Ohori","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B215","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1002\/ejhf.2860","article-title":"Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis","volume":"25","author":"Anker","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B216","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/ehf2.14177","article-title":"Systematic review and meta-analysis of intravenous iron-carbohydrate complexes in HFrEF patients with iron deficiency","volume":"10","author":"Sindone","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B217","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/ehf2.14310","article-title":"Intravenous iron infusion in patients with heart failure: a systematic review and study-level meta-analysis","volume":"10","author":"Salah","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B218","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/ehf2.14905","article-title":"Intravenous iron therapy for heart failure and iron deficiency: an updated meta-analysis of randomized clinical trials","volume":"12","author":"Ahmed","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B219","doi-asserted-by":"publisher","first-page":"7785","DOI":"10.1007\/s12035-024-04077-9","article-title":"Cell-permeable HSP70 protects neurons and astrocytes against cell death in the rotenone-induced and familial models of Parkinson's disease","volume":"61","author":"Vinokurov","year":"2024","journal-title":"Mol Neurobiol"},{"key":"2026050209115475600_xuag015-B220","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1002\/ejhf.3394","article-title":"Administration of ferric derisomaltose for iron deficiency and heart failure during hospital admission or at the clinic\u2014insights from the IRONMAN trial","volume":"26","author":"Lee","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B221","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1002\/ehf2.14742","article-title":"Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction","volume":"11","author":"Docherty","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B222","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ejhf.2992","article-title":"Erythropoietic response after intravenous iron in patients with heart failure and reduced ejection fraction with and without background treatment with sodium-glucose cotransporter 2 inhibitors","volume":"25","author":"Marques","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B223","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1002\/ejhf.3064","article-title":"Sodium\u2013glucose cotransporter 2 inhibitors on top of intravenous iron in patients with heart failure and iron deficiency: any incremental effect?","volume":"25","author":"Savarese","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B224","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1002\/ehf2.14630","article-title":"Improvement in left atrial strain following ferric carboxymaltose in heart failure: an analysis of the Myocardial-IRON trial","volume":"11","author":"Santas","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B225","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1002\/ejhf.3238","article-title":"Iron homeostasis, recycling and vulnerability in the stressed kidney: a neglected dimension of iron-deficient heart failure","volume":"26","author":"Packer","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B226","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/ejhf.3347","article-title":"Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases","volume":"26","author":"Seferovi\u0107","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B227","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1002\/ejhf.3381","article-title":"Diabetic myocardial disorder\u2014a complex interaction","volume":"26","author":"Marx-Sch\u00fctt","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B228","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1002\/ehf2.15115","article-title":"A machine learning tool for identifying newly diagnosed heart failure in individuals with known diabetes in primary care","volume":"12","author":"W\u00e4ndell","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B229","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1002\/ehf2.14280","article-title":"Diabetic microvascular complications predicts non-heart failure with reduced ejection fraction in type 2 diabetes","volume":"10","author":"Tochiya","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B230","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1002\/ehf2.14743","article-title":"Increased interleukin-6 is associated with higher risk of heart failure in people with type 2 diabetes","volume":"11","author":"Remmelzwaal","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B231","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/ehf2.14872","article-title":"Adverse plasma branched-chain amino acid profile mirrors fatty muscle degeneration in diabetic heart failure patients","volume":"11","author":"Kouzu","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B232","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ehf2.14404","article-title":"Activating transcription factor 4 drives the progression of diabetic cardiac fibrosis","volume":"10","author":"Li","year":"2023","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B233","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1002\/ejhf.3604","article-title":"Empagliflozin's anti-inflammatory spectrum in type 2 diabetes mellitus: piecing together the puzzle","volume":"27","author":"Van Linthout","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B234","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1002\/ejhf.3566","article-title":"Unlocking the power of empagliflozin: rescuing inflammation in hyperglycaemia-exposed human cardiomyocytes through comprehensive multi-level analysis","volume":"27","author":"Benedetti","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B235","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1002\/ehf2.14877","article-title":"Type 2 diabetes mellitus and cardiovascular health: evidence of causal relationships in a European ancestry population","volume":"11","author":"Ruan","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B236","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/ejhf.3269","article-title":"Effect of dapagliflozin in patients with diabetes and heart failure with mildly reduced or preserved ejection fraction according to background glucose-lowering therapy: a pre-specified analysis of the DELIVER trial","volume":"26","author":"Lassen","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B237","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/ejhf.3548","article-title":"Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: a pre-specified analysis of the EMPACT-MI trial","volume":"27","author":"Petrie","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B238","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1002\/ehf2.15036","article-title":"Meta-analysis of sotagliflozin, a dual sodium-glucose-cotransporter 1\/2 inhibitor, for heart failure in type 2 diabetes","volume":"12","author":"Bantounou","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B239","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1002\/ehf2.14726","article-title":"Comparison of cardiovascular outcomes of new antihyperglycemic agents in Type 2 Diabetes Mellitus: a meta-analysis","volume":"11","author":"Zhou","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B240","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1002\/ejhf.2967","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure: potential decongestive mechanisms and current clinical studies","volume":"25","author":"Biegus","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B241","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/ejhf.3586","article-title":"Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant-level pooled analysis of the CANVAS and CREDENCE trials","volume":"27","author":"Chatur","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B242","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/ejhf.3464","article-title":"Timing of sodium-glucose cotransporter 2 inhibitor initiation and post-discharge outcomes in acute heart failure with diabetes: a population-based cohort study","volume":"27","author":"Wu","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B243","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/ejhf.3262","article-title":"Association of sodium-glucose cotransporter 2 inhibitors with changes in comprehensive geriatric assessment in elderly diabetic patients with heart failure: data from MAGIC-HF","volume":"26","author":"Armentaro","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B244","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/ehf2.14962","article-title":"Finerenone and left ventricular hypertrophy in chronic kidney disease and type 2 diabetes","volume":"12","author":"Filippatos","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B245","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: the EXSCEL trial","volume":"27","author":"Neves","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B246","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/ejhf.2969","article-title":"Quantitative fluid overload in severe aortic stenosis refines cardiac damage and associates with worse outcomes","volume":"25","author":"Halavina","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B247","doi-asserted-by":"publisher","first-page":"3488","DOI":"10.1002\/ehf2.14832","article-title":"Transcatheter aortic valve replacement for aortic regurgitation: a systematic review and meta-analysis","volume":"11","author":"Liu","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B248","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1002\/ehf2.14887","article-title":"Heart failure hospitalization following surgical or transcatheter aortic valve implantation in low-risk aortic stenosis","volume":"11","author":"Lopez-Martinez","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B249","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1002\/ejhf.3009","article-title":"Prevalence and predictive value of fluid overload in patients with severe symptomatic aortic valve stenosis","volume":"25","author":"van Bergeijk","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B250","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1002\/ejhf.3337","article-title":"Prevalence and prognosis of aortic valve diseases in patients hospitalized with heart failure with mildly reduced ejection fraction","volume":"26","author":"Schupp","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B251","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/ejhf.3151","article-title":"Transcatheter aortic valve replacement in heart failure","volume":"26","author":"Parikh","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B252","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1002\/ejhf.70023","article-title":"Management of aortic stenosis and chronic heart failure: a clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC","volume":"27","author":"Adamo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B253","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1002\/ejhf.2908","article-title":"Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"25","author":"Shahim","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B254","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1002\/ejhf.3329","article-title":"Right ventricular dysfunction and impaired right ventricular-pulmonary arterial coupling in paradoxical low-flow, low-gradient aortic stenosis","volume":"26","author":"Nies","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B255","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/ejhf.3624","article-title":"Characteristics, determinants, and prognostic impact of severe tricuspid regurgitation in patients with atrial functional mitral regurgitation: insights from the REVEAL-AFMR registry","volume":"27","author":"Kaneko","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B256","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/ejhf.3322","article-title":"Cardiac function, haemodynamics, and valve competence with exercise in patients with heart failure with preserved ejection fraction and mild to moderate secondary mitral regurgitation","volume":"26","author":"Harada","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B257","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/ejhf.2820","article-title":"Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF-2 trial","volume":"25","author":"Pagnesi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B258","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ejhf.2797","article-title":"Transcatheter mitral valve replacement or repair for secondary mitral regurgitation: a propensity score-matched analysis","volume":"25","author":"Ludwig","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B259","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ehf2.14705","article-title":"Guideline-directed medical therapy assessment in heart failure patients undergoing percutaneous mitral valve repair","volume":"11","author":"Kresoja","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B260","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/ejhf.3288","article-title":"Mitral regurgitation and heart failure with preserved ejection fraction: should we treat the muscle, the valve, or both?","volume":"26","author":"Riccardi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B261","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1002\/ejhf.3327","article-title":"EXPANDing horizons: optimizing heart failure management following transcatheter edge-to-edge repair of mitral regurgitation","volume":"26","author":"von Stein","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B262","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.3250","article-title":"Impact of heart failure hospitalizations on clinical outcomes after mitral transcatheter edge-to-edge repair: results from the EXPAND study","volume":"26","author":"Kessler","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B263","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3725","article-title":"Prognostic value of NT-proBNP in patients with primary mitral regurgitation undergoing transcatheter edge-to-edge repair","volume":"27","author":"von Stein","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B264","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1002\/ejhf.3582","article-title":"Transcatheter edge-to-edge repair in severe mitral regurgitation following acute myocardial infarction\u2014aetiology-based analysis","volume":"27","author":"Haberman","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B265","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1002\/ejhf.3605","article-title":"Rescuing patients with post-myocardial infarction mitral regurgitation with transcatheter edge-to-edge repair: a salvation for all mechanisms of mitral regurgitation","volume":"27","author":"Vazir","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B266","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1002\/ejhf.3559","article-title":"Long-term results of tricuspid valve transcatheter edge-to-edge repair in patients with cardiac implantable electronic devices","volume":"27","author":"Stolz","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B267","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1002\/ejhf.3599","article-title":"Tricuspid regurgitation risk scores in patients undergoing tricuspid valve transcatheter edge-to-edge repair","volume":"27","author":"Ennin","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B268","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1002\/ejhf.3157","article-title":"Tricuspid regurgitation: frequency, clinical presentation, management and outcome among patients with severe left-sided valvular heart disease in Europe. Insights from the ESC-EORP Valvular Heart Disease II survey","volume":"26","author":"Dreyfus","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B269","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/ejhf.3254","article-title":"Letting go of restraint: tricuspid valve intervention in heart failure with preserved ejection fraction","volume":"26","author":"Rao","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B270","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1002\/ejhf.3195","article-title":"Implications of tricuspid regurgitation and right ventricular volume overload in patients with heart failure with preserved ejection fraction","volume":"26","author":"Kresoja","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B271","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ejhf.3106","article-title":"Epidemiology, pathophysiology, diagnosis and management of chronic right-sided heart failure and tricuspid regurgitation. A clinical consensus statement of the Heart Failure Association (HFA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC","volume":"26","author":"Adamo","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B272","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1002\/ehf2.15327","article-title":"Quality of life after transcatheter tricuspid valve repair: results from the Tri.FR trial","volume":"12","author":"Istratoaie","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B273","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/ejhf.3183","article-title":"Changes in right ventricular function and clinical outcomes following tricuspid transcatheter edge-to-edge repair","volume":"26","author":"Tanaka","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B274","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1002\/ejhf.3332","article-title":"Right ventricular function profits from tricuspid regurgitation reduction following tricuspid transcatheter edge-to-edge repair: when is it never too late?","volume":"26","author":"Agricola","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B275","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/ejhf.3757","article-title":"Heart failure hospitalizations and clinical outcomes in patients undergoing tricuspid transcatheter edge-to-edge repair: insights from EuroTR","volume":"27","author":"Tomasoni","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B276","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1002\/ejhf.3623","article-title":"Malnutrition and outcomes in patients with tricuspid regurgitation undergoing transcatheter tricuspid valve repair","volume":"27","author":"Pagnesi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B277","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ejhf.3147","article-title":"Neuromodulation interventions in the management of heart failure","volume":"26","author":"Abdin","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B278","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1002\/ehf2.15401","article-title":"Phenotype characterization of heart failure with preserved ejection fraction in medical device and surgical trials","volume":"12","author":"Araz","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B279","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1002\/ehf2.15114","article-title":"Interventional therapies for chronic heart failure: an overview of recent developments","volume":"12","author":"Guo","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B280","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/ehf2.15067","article-title":"Device-therapy in chronic heart failure: cardiac contractility modulation vs cardiac resynchronization therapy","volume":"12","author":"Yuecel","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B281","doi-asserted-by":"publisher","first-page":"12929","DOI":"10.1038\/s41598-024-63742-0","article-title":"Effectiveness of remote pulmonary artery pressure estimating in heart failure: systematic review and meta-analysis","volume":"14","author":"Urban","year":"2024","journal-title":"Sci Rep"},{"key":"2026050209115475600_xuag015-B282","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S0140-6736(15)00723-0","article-title":"Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial","volume":"387","author":"Abraham","year":"2016","journal-title":"Lancet"},{"key":"2026050209115475600_xuag015-B283","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S0140-6736(11)60101-3","article-title":"Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial","volume":"377","author":"Abraham","year":"2011","journal-title":"Lancet"},{"key":"2026050209115475600_xuag015-B284","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(21)01754-2","article-title":"Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial","volume":"398","author":"Lindenfeld","year":"2021","journal-title":"Lancet"},{"key":"2026050209115475600_xuag015-B285","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1016\/S0140-6736(23)00923-6","article-title":"Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial","volume":"401","author":"Brugts","year":"2023","journal-title":"Lancet"},{"key":"2026050209115475600_xuag015-B286","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/ejhf.3619","article-title":"Remote pulmonary artery pressure-guided management of patients with heart failure: a clinical consensus statement of the Heart Failure Association (HFA) of the ESC","volume":"27","author":"Bayes-Genis","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B287","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1002\/ejhf.3303","article-title":"Serial cardiac biomarkers, pulmonary artery pressures and traditional parameters of fluid status in relation to prognosis in patients with chronic heart failure: design and rationale of the BioMEMS study","volume":"26","author":"Allach","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B288","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ejhf.3357","article-title":"Identifying reliable biomarkers for pulmonary congestion: toward a close yet sustainable heart failure follow-up","volume":"26","author":"Panichella","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B289","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1002\/ejhf.2839","article-title":"Inferior vena cava monitoring in heart failure: don't wait until the last drop makes the cup run over","volume":"25","author":"Pagnesi","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B290","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.jchf.2023.05.034","article-title":"Congestion and decongestion assessment in heart failure: pressure, volume, or both?","volume":"11","author":"Biegus","year":"2023","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B291","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ejhf.2822","article-title":"Safety and performance of a novel implantable sensor in the inferior vena cava under acute and chronic intravascular volume modulation","volume":"25","author":"Sheridan","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B292","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.jchf.2025.01.019","article-title":"First-in-human implantable inferior vena cava sensor for remote care in heart failure: FUTURE-HF","volume":"13","author":"Kalra","year":"2025","journal-title":"JACC Heart Fail"},{"key":"2026050209115475600_xuag015-B293","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.70091","article-title":"Clinical profiles and prognostic impact of residual intravascular and tissue congestion in acute heart failure","volume":"27","author":"Ceelen","year":"11, 2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B294","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1002\/ehf2.14688","article-title":"Computed tomography or chest X-ray to assess pulmonary congestion in dyspnoeic patients with acute heart failure","volume":"11","author":"Miger","year":"2024","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B295","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1002\/ehf2.14982","article-title":"Biomarkers of lung congestion and injury in acute heart failure","volume":"12","author":"Guazzi","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B296","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1002\/ejhf.3290","article-title":"Measuring congestion with a non-invasive monitoring device in heart failure and haemodialysis: CONGEST-HF","volume":"26","author":"Curtain","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B297","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10741-024-10449-z","article-title":"Harnessing the lymphatic system","volume":"30","author":"Ponikowska","year":"2025","journal-title":"Heart Fail Rev"},{"key":"2026050209115475600_xuag015-B298","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ejhf.3655","article-title":"Lower extremity lymphatic flow is associated with diuretic response in acute heart failure","volume":"27","author":"Ponikowska","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B299","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.jacbts.2024.02.016","article-title":"Lower extremity lymphatic flow\/drainage assessment by indocyanine green fluorescent lymphography in heart failure patients","volume":"9","author":"Ponikowska","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"2026050209115475600_xuag015-B300","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/ehf2.15192","article-title":"Design and rationale of the eLym system for decompensation of excess lymphatic fluid via the thoracic duct in acute heart failure (DELTA-HF)","volume":"12","author":"Biegus","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B301","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1002\/ejhf.3196","article-title":"Serial direct sodium removal in patients with heart failure and diuretic resistance","volume":"26","author":"Rao","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B302","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1002\/ejhf.3258","article-title":"Baroreceptors as a target of device-based neuromodulation in heart failure: long-term outcomes","volume":"26","author":"Grassi","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B303","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/ejhf.3232","article-title":"Baroreflex activation therapy in patients with heart failure and a reduced ejection fraction: long-term outcomes","volume":"26","author":"Zile","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B304","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/ejhf.2853","article-title":"The win ratio method in heart failure trials: lessons learnt from EMPULSE","volume":"25","author":"Pocock","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B305","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/ehf2.15074","article-title":"Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure","volume":"12","author":"Abraham","year":"2025","journal-title":"ESC Heart Fail"},{"key":"2026050209115475600_xuag015-B306","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/ejhf.3139","article-title":"Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: rationale and design of the HF-REVERT trial","volume":"26","author":"Bauersachs","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B307","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1002\/ejhf.3453","article-title":"The spironolactone initiation registry randomized interventional trial in heart failure with preserved ejection fraction (SPIRRIT-HFpEF): rationale and design","volume":"26","author":"Lund","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026050209115475600_xuag015-B308","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1002\/ejhf.3476","article-title":"Multicentre, randomized, double-blind, prospective study on the effects of ImmunoAdSorptiOn on cardiac function in patients with Dilated CardioMyopathy (IASO-DCM): rationale and design","volume":"26","author":"D\u00f6rr","year":"2024","journal-title":"Eur J Heart Fail"}],"container-title":["European Journal of Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjhf\/advance-article-pdf\/doi\/10.1093\/ejhf\/xuag015\/66430900\/xuag015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/1\/66430900\/xuag015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjhf\/article-pdf\/28\/1\/1\/66430900\/xuag015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:12:04Z","timestamp":1777727524000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjhf\/article\/28\/1\/1\/8427482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":308,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,17]]},"published-print":{"date-parts":[[2026,5,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ejhf\/xuag015","relation":{},"ISSN":["1388-9842","1879-0844"],"issn-type":[{"value":"1388-9842","type":"print"},{"value":"1879-0844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2026,1]]}}}